BIOMAT Database Logo BIOMAT Database Logo

Treatment of advanced Hodgkin's disease with vinblastine (NSC-49842) or procarbazine (NSC-77213). 1969

F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001565 Benzoates Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure. Benzoate,Benzoic Acids,Acids, Benzoic
D014747 Vinblastine Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) Vincaleukoblastine,Cellblastin,Lemblastine,Velban,Velbe,Vinblastin Hexal,Vinblastina Lilly,Vinblastine Sulfate,Vinblastinsulfat-Gry,Sulfate, Vinblastine

Related Publications

F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
Treatment of malignant melanoma with vinblastine (NSC-49842), procarbazine (NSC-77213), and actinomycin D (NSC-3053).
January 1975, Cancer chemotherapy reports,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
Procarbazine (NSC-77213) in the treatment of advanced bronchogenic carcinoma.
April 1969, Cancer chemotherapy reports,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease.
December 1971, Cancer chemotherapy reports,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
Procarbazine (NSC-77213) and multiple myeloma.
August 1970, Cancer chemotherapy reports,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
Preclinical toxicologic study of procarbazine (NSC-77213).
January 1973, Cancer chemotherapy reports. Part 3,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
March 1976, Cancer treatment reports,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
"HISTIOCYTOSIS X" TREATED WITH VINBLASTINE SULFATE (NSC-49842).
July 1964, Cancer chemotherapy reports,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
Vinblastine sulfate (NSC-49842) in the treatment of bronchogenic carcinoma.
December 1970, Cancer chemotherapy reports,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
Comparative effects of vinblastine and procarbazine in advanced Hodgkin's disease.
September 1969, European journal of cancer,
F A Flatow, and J E Ultmann, and G A Hyman, and F M Muggia
Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease.
May 1977, Cancer,
Copied contents to your clipboard!